Autoantibody panel for autoimmune encephalitis
Calderón M, García Martí S, Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32016000913
Spanish
Authors' recommendations:
The evidence on the use of autoantibodies for the diagnosis of autoimmune encephalitis is of low quality. No randomized controlled clinical trials assessing clinical outcomes after changing the autoantibody-guided treatment strategy have been found. For most autoantibodies, no diagnostic accuracy studies have been found. The observational studies selected only show the association between the frequency of different autoantibodies detection and autoimmune encephalitis.
No health technology assessments evaluating any autoantibody for autoimmune encephalitis have been found. The clinical practice guidelines recommend anti-NMDA for the definitive diagnosis of anti-NMDA encephalitis and anti-LGI1, anti-GABA and anti-AMPA autoantibodies when there is potential diagnosis of limbic encephalitis.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Autoantibodies
- Brain Diseases
- Encephalitis
- Hashimoto Disease
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.